This company has been marked as potentially delisted and may not be actively trading. Immuron (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrendsBuy This Stock IMRN vs. VRCA, RFL, XLO, CNTB, MRSN, SPRO, RNTX, ANEB, AADI, and APLTShould you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Verrica Pharmaceuticals (VRCA), Rafael (RFL), Xilio Therapeutics (XLO), Connect Biopharma (CNTB), Mersana Therapeutics (MRSN), Spero Therapeutics (SPRO), Rein Therapeutics (RNTX), Anebulo Pharmaceuticals (ANEB), Aadi Bioscience (AADI), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical preparations" industry. Immuron vs. Verrica Pharmaceuticals Rafael Xilio Therapeutics Connect Biopharma Mersana Therapeutics Spero Therapeutics Rein Therapeutics Anebulo Pharmaceuticals Aadi Bioscience Applied Therapeutics Verrica Pharmaceuticals (NASDAQ:VRCA) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation. Do institutionals and insiders hold more shares of VRCA or IMRN? 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 42.6% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, VRCA or IMRN? Immuron has lower revenue, but higher earnings than Verrica Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$7.57M5.63-$67M-$1.54-0.30Immuron$3.21M3.24-$4.55MN/AN/A Does the MarketBeat Community believe in VRCA or IMRN? Immuron received 21 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. Likewise, 67.87% of users gave Immuron an outperform vote while only 63.26% of users gave Verrica Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVerrica PharmaceuticalsOutperform Votes16763.26% Underperform Votes9736.74% ImmuronOutperform Votes18867.87% Underperform Votes8932.13% Does the media favor VRCA or IMRN? In the previous week, Immuron had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Immuron's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Verrica Pharmaceuticals Very Positive Immuron Neutral Which has more volatility & risk, VRCA or IMRN? Verrica Pharmaceuticals has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Immuron has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Is VRCA or IMRN more profitable? Immuron has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. Immuron's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Verrica Pharmaceuticals-625.06% -591.84% -141.63% Immuron N/A N/A N/A Do analysts rate VRCA or IMRN? Verrica Pharmaceuticals presently has a consensus price target of $9.50, suggesting a potential upside of 1,946.97%. Immuron has a consensus price target of $5.00, suggesting a potential upside of 180.43%. Given Verrica Pharmaceuticals' higher possible upside, equities analysts plainly believe Verrica Pharmaceuticals is more favorable than Immuron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Immuron 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryImmuron beats Verrica Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Immuron News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricImmuronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.03M$6.74B$5.48B$7.80BDividend YieldN/A3.11%5.42%4.24%P/E RatioN/A7.2722.3118.46Price / Sales3.24241.32394.17104.18Price / CashN/A65.8538.1834.62Price / Book1.226.356.724.21Net Income-$4.55M$143.17M$3.22B$248.18M Immuron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNImmuron1.2213 of 5 stars$1.78-10.9%$5.00+180.4%-32.5%$11.03M$3.21M0.00N/AShort Interest ↑VRCAVerrica Pharmaceuticals4.2935 of 5 stars$0.47-5.1%$9.50+1,941.3%-93.2%$42.71M$7.57M-0.2540Positive NewsRFLRafael0.8086 of 5 stars$1.70+1.2%N/A-0.3%$42.35M$706,000.00-1.0220Short Interest ↓XLOXilio Therapeutics3.1136 of 5 stars$0.82+8.4%$4.00+390.8%-28.0%$42.20M$6.34M-0.4770Gap DownCNTBConnect Biopharma2.5828 of 5 stars$0.75+0.8%$8.00+973.8%-39.6%$41.24M$24.12M0.00110Short Interest ↑MRSNMersana Therapeutics3.7758 of 5 stars$0.33-7.8%$4.00+1,123.6%-86.9%$40.74M$40.50M-0.54150SPROSpero Therapeutics4.3204 of 5 stars$0.73-3.9%$5.00+589.7%-51.4%$40.53M$27.40M10.36150Short Interest ↑News CoverageRNTXRein TherapeuticsN/A$1.78+4.7%N/AN/A$39.15MN/A-0.579ANEBAnebulo Pharmaceuticals2.0058 of 5 stars$0.95-5.9%$8.00+742.1%-57.5%$39.03MN/A-3.394Short Interest ↑AADIAadi BioscienceN/A$1.57+1.9%$1.67+6.2%-17.1%$38.77M$25.07M-0.6940Upcoming EarningsAPLTApplied Therapeutics4.0654 of 5 stars$0.33-0.1%$6.10+1,734.0%-90.8%$38.70M$455,000.00-0.2130News CoveragePositive News Related Companies and Tools Related Companies VRCA Competitors RFL Competitors XLO Competitors CNTB Competitors MRSN Competitors SPRO Competitors RNTX Competitors ANEB Competitors AADI Competitors APLT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRN) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
